Inaphaea Contract Award

Inaphaea is pleased to confirm the execution of a revenue-bearing contract for the provision of Patient Derived Cell ("PDC") based services with a new client; a US-based biotech company. The contract is a multi-stage project and encompasses analysis and provision of RNA data, acquired as part of the scientific package from Imagen Therapeutics, in addition to bespoke cell-based screening in the laboratory. This initial phase of work will commence immediately, and the project is structured to build a long term working relationship with the client with scope to include potential future material revenue generation.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "It's encouraging to have secured this contract in the exciting area of immuno-oncology, which will be a great opportunity to showcase our skills and leveraging our PDCs in this area.

"The US biotech market is a strong location to seek clients for Inaphaea and this contract is a positive step towards establishing our brand in further geographical regions".